Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bartlomiej Pycinski

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 7, 2016
Patient Specific Phantom in bimodal image navigation systemJan Juszczyk, Bartlomiej Pycinski, Ewa Pietka
Plos One|July 20, 2016
Time-Of-Flight Camera, Optical Tracker and Computed Tomography in Pairwise Data RegistrationBartlomiej Pycinski, Joanna Czajkowska, Pawel Badura, et al.
Breast Cancer Research : BCR|December 10, 2025
Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxelMarcin Kubeczko, Andrea d'Amico, Olgierd Chrabanski, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 7, 2016
Patient Specific Phantom in bimodal image navigation systemJan Juszczyk, Bartlomiej Pycinski, Ewa Pietka
Plos One|July 20, 2016
Time-Of-Flight Camera, Optical Tracker and Computed Tomography in Pairwise Data RegistrationBartlomiej Pycinski, Joanna Czajkowska, Pawel Badura, et al.
Breast Cancer Research : BCR|December 10, 2025
Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxelMarcin Kubeczko, Andrea d'Amico, Olgierd Chrabanski, et al.
Pageof 1